About CytoAgents
Our Mission
CytoAgents is focused on the development of innovative pharmaceutical products for the treatment of a pipeline of indications driven by the hyperactivation and dysregulation of the immune system.
Our Difference
CytoAgents has successfully completed Phase 1a human clinical trial focused on safety
CT01681’s ability to safely modulate the cytokine response makes it an ideal solution to address inflammation in the tumor microenvironment and toxicity driven by hyperactivated cytokines
CTO1681: Orally bioavailable, steroid sparing immunomodulator for multiple indication driven by cytokine inducing inflammation
Our Team
CytoAgents has built a team comprised of world-renowned clinicians and scientists, clinical drug development and regulatory experts, as well as those skilled in the areas of patent law, business development and finance. Together we have built a culture of collaboration, excellence, and urgency. We have great momentum built through value creation in a very rapid period of time.
Meet the TeamCompany Highlights
Investors
In the fight against Cytokine Release Syndrome, CytoAgents has been able to make great progress. After having successfully completed our initial Phase 1 Human Clinical Trial. We are currently enrolling patients for a Phase 1b/2a trial for CAR T Cell therapy related CRS
Join us as we transform the treatment of inflammation across a broad pipeline of indications.
Executive Summary
Interested in Learning More About CytoAgents?
Join us in our journey to protect patients from the toxicities of uncontrolled inflammation.